United Therapeutics Corp. (UTHR) Holder Evanston Investments Dba Evanston Advisors Raised Position by $422,625; Sarissa Capital Management LP Lifted Medicines Co (MDCO) Holding by $4.59 Million as Share Value Rose

April 18, 2018 - By Peter Erickson

The Medicines Company (NASDAQ:MDCO) Logo

Alex Denner increased its stake in Medicines Co (MDCO) by 9.7% based on its latest 2017Q4 regulatory filing with the SEC. Sarissa Capital Management Lp bought 170,000 shares as the company’s stock rose 23.35% while stock markets declined. The hedge fund run by Alex Denner held 1.92M shares of the major pharmaceuticals company at the end of 2017Q4, valued at $52.55 million, up from 1.75 million at the end of the previous reported quarter. Sarissa Capital Management Lp who had been investing in Medicines Co for a number of months, seems to be bullish on the $2.22 billion market cap company. The stock decreased 0.39% or $0.12 during the last trading session, reaching $30.28. About 15,325 shares traded. The Medicines Company (NASDAQ:MDCO) has declined 34.73% since April 18, 2017 and is downtrending. It has underperformed by 46.28% the S&P500.

Evanston Investments Inc Dba Evanston Advisors increased its stake in United Therapeutics Corp. (UTHR) by 5.1% based on its latest 2017Q4 regulatory filing with the SEC. Evanston Investments Inc Dba Evanston Advisors bought 2,875 shares as the company’s stock declined 21.89% with the market. The institutional investor held 59,199 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $8.76 million, up from 56,324 at the end of the previous reported quarter. Evanston Investments Inc Dba Evanston Advisors who had been investing in United Therapeutics Corp. for a number of months, seems to be bullish on the $4.80 billion market cap company. The stock decreased 2.65% or $3.02 during the last trading session, reaching $111.07. About 27,996 shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has declined 23.69% since April 18, 2017 and is downtrending. It has underperformed by 35.24% the S&P500.

Since October 19, 2017, it had 0 insider purchases, and 11 sales for $26.94 million activity.

Investors sentiment increased to 1.14 in 2017 Q4. Its up 0.15, from 0.99 in 2017Q3. It improved, as 26 investors sold UTHR shares while 112 reduced holdings. 53 funds opened positions while 105 raised stakes. 40.90 million shares or 1.42% less from 41.49 million shares in 2017Q3 were reported. 14,829 are owned by Hays Advisory Ltd Company. Weaver C Barksdale Assocs invested in 68 shares or 0.01% of the stock. Axa accumulated 0.04% or 70,321 shares. Brandywine Glob Limited Company accumulated 105 shares. Apg Asset Nv invested in 705,900 shares. American Int owns 91,580 shares for 0.04% of their portfolio. Hanson Mcclain Incorporated holds 50 shares. Bailard accumulated 0.03% or 2,800 shares. Alliancebernstein Limited Partnership has invested 0% in United Therapeutics Corporation (NASDAQ:UTHR). Advantus Inc reported 0.02% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR). Riverhead Capital Mgmt Limited Com holds 0.05% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR) for 7,500 shares. Vanguard Group Inc Inc invested 0.02% in United Therapeutics Corporation (NASDAQ:UTHR). Legal General Gru Public Ltd Com reported 91,742 shares stake. Matarin Capital Mngmt Limited Liability invested 0.04% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR). Twin Tree Management Ltd Partnership invested in 5,904 shares or 0.01% of the stock.

Evanston Investments Inc Dba Evanston Advisors, which manages about $372.58 million and $417.70M US Long portfolio, decreased its stake in Reinsurance Group Of America Inc. (NYSE:RGA) by 3,617 shares to 56,401 shares, valued at $8.80M in 2017Q4, according to the filing. It also reduced its holding in Ishares Gold Trust (IAU) by 34,310 shares in the quarter, leaving it with 1.34M shares, and cut its stake in Applied Materials Inc. (NASDAQ:AMAT).

Among 12 analysts covering United Therapeutics (NASDAQ:UTHR), 2 have Buy rating, 3 Sell and 7 Hold. Therefore 17% are positive. United Therapeutics had 32 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was upgraded by Ladenburg Thalmann to “Buy” on Friday, October 28. H.C. Wainwright maintained the stock with “Hold” rating in Thursday, October 26 report. The stock has “Hold” rating by Argus Research on Tuesday, May 24. H.C. Wainwright maintained United Therapeutics Corporation (NASDAQ:UTHR) rating on Friday, July 28. H.C. Wainwright has “Hold” rating and $9500 target. As per Thursday, February 22, the company rating was maintained by Credit Suisse. The firm earned “Buy” rating on Friday, July 31 by Argus Research. The rating was maintained by Barclays Capital on Thursday, February 22 with “Underweight”. The stock of United Therapeutics Corporation (NASDAQ:UTHR) has “Buy” rating given on Tuesday, February 27 by Wedbush. The rating was maintained by Cowen & Co with “Hold” on Thursday, October 26. Ladenburg Thalmann downgraded the stock to “Neutral” rating in Thursday, February 23 report.

Investors sentiment increased to 1.25 in 2017 Q4. Its up 0.47, from 0.78 in 2017Q3. It improved, as 26 investors sold MDCO shares while 51 reduced holdings. 28 funds opened positions while 68 raised stakes. 89.44 million shares or 5.03% more from 85.15 million shares in 2017Q3 were reported. Pinnacle Assocs Ltd owns 0.61% invested in The Medicines Company (NASDAQ:MDCO) for 1.17M shares. Antipodean Advsrs Ltd has invested 2.18% in The Medicines Company (NASDAQ:MDCO). Ls Inv Ltd owns 2,145 shares. Aperio Gp Limited Liability Company reported 25,368 shares or 0% of all its holdings. Millennium Mgmt Ltd Limited Liability Company invested in 0.01% or 256,352 shares. Colorado-based Pub Employees Retirement Association Of Colorado has invested 0% in The Medicines Company (NASDAQ:MDCO). Wellington Gp Ltd Liability Partnership reported 0.06% stake. Artal Grp Sa holds 0.08% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 200,000 shares. Partner Fund Limited Partnership invested in 1.2% or 1.85 million shares. Voya Inv Ltd Liability accumulated 31,041 shares. 268,240 are owned by Highvista Strategies Ltd Llc. Mason Street Advisors Ltd Llc holds 16,685 shares or 0.01% of its portfolio. Profund Advsrs Limited Co owns 12,214 shares or 0.01% of their US portfolio. Cwm Lc has 0% invested in The Medicines Company (NASDAQ:MDCO). Gemmer Asset Management Ltd Limited Liability Company owns 92 shares.

Among 11 analysts covering The Medicines Co (NASDAQ:MDCO), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. The Medicines Co had 37 analyst reports since August 28, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Tuesday, September 12 report. H.C. Wainwright initiated the shares of MDCO in report on Monday, December 5 with “Buy” rating. The firm has “Buy” rating by Cowen & Co given on Wednesday, August 9. The firm earned “Outperform” rating on Tuesday, November 8 by RBC Capital Markets. RBC Capital Markets maintained The Medicines Company (NASDAQ:MDCO) on Monday, November 16 with “Outperform” rating. The stock of The Medicines Company (NASDAQ:MDCO) earned “Buy” rating by Citigroup on Monday, January 22. The company was maintained on Monday, August 31 by Oppenheimer. Oppenheimer maintained it with “Hold” rating and $5000 target in Thursday, August 10 report. The stock of The Medicines Company (NASDAQ:MDCO) earned “Neutral” rating by Citigroup on Monday, July 17. The rating was maintained by Oppenheimer on Wednesday, July 12 with “Hold”.

Since December 7, 2017, it had 1 insider buy, and 2 insider sales for $1.36 million activity. $241,950 worth of The Medicines Company (NASDAQ:MDCO) shares were sold by CROUSE WILLIAM. MEANWELL CLIVE sold 136,250 shares worth $3.71M.

United Therapeutics Corporation (NASDAQ:UTHR) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>